Autolus Therapeutics (AUTL) Gross Margin (2024 - 2026)
Autolus Therapeutics' (AUTL) quarterly Gross Margin came in at 4.29% in Q4 2025, up 3916123.0% YoY from N/an in Q4 2024, and up 87.81% on a QoQ basis from 35.15% in Q3 2025.
Powered by 
Analysis
Autolus Therapeutics (AUTL) Gross Margin (2024 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 2 years of Gross Margin data on file, last reported at 4.29% in Q4 2025.
- Quarterly Gross Margin rose 3916123.0% year-over-year to 4.29% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 27.83% (down 1541.0% YoY) and the FY2025 annual result came in at 27.83%, down 1531.0% from the prior year.
- Gross Margin climbed to 4.29% in Q4 2025, from 35.15% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2024 to a low of 39165.52% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Autolus Therapeutics | 594.86 Mn | 393.23 Mn | 25.22 Mn | 55.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 55.20% |
| Dec 31, 2025 | -4.29% |
| Sep 30, 2025 | -35.15% |
| Jun 30, 2025 | -16.83% |
| Mar 31, 2025 | -99.86% |
| Dec 31, 2024 | -39,165.52% |
| Mar 31, 2024 | 100.00% |